PHILADELPHIA -- The Impella mechanical support device, frequently used in patients in cardiogenic shock who are undergoing percutaneous coronary interventions, was more expensive than intra-aortic ...

Compared with no added support, use of the Impella percutaneous left ventricular assist device (Abiomed) in patients undergoing high-risk nonemergent PCI is associated with more periprocedural MI ...

April 3, 2011 (New Orleans, Louisiana) — Even though the PROTECT II trial of the Impella 2.5 circulatory assist device (Abiomed, Danvers, MA) was stopped early for futility, the trial's lead ...

A pricey high-tech pump that maintains blood flow during heart procedures could be more dangerous to patients than its low-tech predecessor, a pair of new studies finds. The Impella device is ...

ORLANDO, Fla.--(BUSINESS WIRE)--The final results of the PROTECT III and Restore EF prospective studies demonstrate improved outcomes for high-risk PCI patients with the use of Impella heart pumps.

PHILADELPHIA, PA—Two large observational studies are casting doubt on how well newer forms of mechanical circulatory support (MCS) are performing in real-world practice in the United States. The ...

An illustration of the Impella 2.5 pump in the heart--Screenshot courtesy of Abio Abiomed ($ABMD) revealed in an SEC filing that the FDA has agreed to forgo an ...

In critically ill patients who require a heart pump to support blood circulation as part of stent procedures, specific heart pumps have been associated with serious complications, according to a new ...

Another observational study has questioned whether Impella ventricular assist pumps (Abiomed) should be used in patients with acute myocardial infarction (MI) complicated by cardiogenic shock (CS), at ...

In a cohort of patients who underwent high-risk PCI, mechanical circulatory support with a microaxial blood pump was linked to lower odds of death, MI and cardiogenic shock compared with use of an ...

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that ...

A pricey high-tech pump that maintains blood flow during heart procedures could be more dangerous to patients than its low-tech predecessor, a pair of recent studies finds. The Impella device is ...